Tiziana Life Sciences (TLSA) announced that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis, ECTRIMS, being held September 24-26, 2025, in Barcelona, Spain. The poster, titled “Study Design of a Phase 2a Double-Blind Placebo-Controlled Trial of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis,” will outline the clinical trial design and objectives for Tiziana’s innovative nasal foralumab program. Nasal foralumab is the first entirely human anti-CD3 monoclonal antibody designed for intranasal delivery, representing a novel approach to modulating the immune system for the treatment of non-active secondary progressive multiple sclerosis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Secures DoD Grant for Spinal Cord Injury Research
- Tiziana Life Sciences announces U.S. DoD awarded research grant to study SCI
- Tiziana Life Sciences CEO Increases Stake Amidst Ongoing Clinical Trials
- Tiziana Life Sciences reports CEO purchased 14,848 shares
- Tiziana Life Sciences CEO Buys Shares, Signaling Confidence in Innovative Therapies